CLINICAL TRIALS
Do you have Nontuberculous
Mycobacterial (NTM) Pulmonary Disease?
You can search for pending or recruiting clinical trials through the National Library of Medicine’s clinical trials website, clinicaltrials.gov.
This site also maintains a list of recruiting studies. If you are a principal investigator or study site and wish to add an IRB-approved trial to our listings, or if you wish to have your study information amended or removed from ntminfo.org, please email ntmmail@ntminfo.org.
CLOFAZIMINE IN THE TREATMENT OF PULMONARY NONTUBERCULOUS MYCOBACTERIUM AVIUM COMPLEX (MAC)
Investigators have developed a randomized, placebo-controlled clinical trial to assess the clinical efficacy and safety of clofazimine when used to treat MAC lung disease. Learn more.
ICoN-1 STUDY OF INHALED CLOFAZIMINE FOR ADULTS WITH NTM CAUSED BY MAC
Randomized, double-blind, placebo-controlled study (Part A) designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT). The primary objective of this study will be to compare the efficacy of Clofazimine Inhalation Suspension versus placebo as assessed by the co-primary endpoints, sputum culture conversion and change in Quality of Life-Bronchiectasis Respiratory Symptoms Score (QoL-B RSS). An open label extension study (Part B) will be offered to qualified participants for treatment with Clofazimine Inhalation Suspension. Learn more.
BRONCHIECTASIS AT-HOME RESEARCH STUDY
The study goal is to allow researchers to enhance our understandings of bronchiectasis, in support of developing new diagnostic and treatment options for patients living with condition. Learn more: https://sanguinebio.com/condition/bronchiectasis/
EVALUATION OF THE LUNG MICROBIOME IN NTM BRONCHIECTASIS
A biomarker cohort study design is proposed to study whether specific airway microbiota alterations are associated with pulmonary Non-tuberculous mycobacteria (NTM) disease. Learn more.
FINDING THE OPTIMAL REGIMEN FOR MYCOBACTERIUM ABSCESSUS TREATMENT
We are looking for people to be part of our Consumer Advisory Group to provide their say on how treatments for a rare lung condition are being tested. Please contact us at formattrial@health.qld.gov.au for further information and to apply! Learn more.
TRIKAFTA FOR PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS
Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight. Additionally, cutaneous punch biopsy material will be collected from each participant to test cellular response to Trikafta. Learn more.
MAC INFECTION AND ENVIRONMENTAL TESTING
MAC infection and environmental testing: A sequencing study that will assess whether the MAC from lung disease patients matches the MAC cultured from the home environment. Learn more
NATIONAL LIBRARY OF MEDICINE CLINICAL TRIALS LISTINGS
Search for pending or recruiting clinical trials on clinicaltrials.gov
PROSPECTIVE ALGORITHM FOR TREATMENT OF NTM IN CYSTIC FIBROSIS (PATIENCE)
STUDY OF MYCOBACTERIAL INFECTIONS
This study will examine the symptoms, course of disease and treatment of non-tuberculous mycobacterial (NTM) infections, as well as the genetics involved in these infections. Learn more.
VOLUNTEERS NEEDED FOR RESEARCH STUDY IN AUSTRALIAN PATIENTS WITH NTM LUNG INFECTION
220,000
ESTIMATED CASES
OF NTM IN THE US
IN 2020
8.2 %
THE RISE IN THE
NUMBER OF NTM CASES
EACH YEAR
2.8m
ANTIBIOTIC-
RESISTANT INFECTIONS
IN THE US EACH YEAR